Cores

Each Core facility is directed by an NIH-funded investigator who is an expert in the field represented by his or her core laboratory. These research services are available to all members at a reduced cost, and in some instances at no cost.

To support our ongoing funding, IDDRC members are expected to cite our Center (“Intellectual and Developmental Disabilities Research Center” - NIH/NICHD P30 HD026979) in all publications that result from work supported by one or more of our Core facilities.

Individuals who are interested in joining the Center or in subscribing to our mailing list should contact Melba Martinez at martinez@email.chop.edu or 215-590-3728.

Administrative Core

The Administrative Core provides the leadership and coordination that has made the Center an effective and cohesive vehicle to advance IDDRC-related research at the University of Pennsylvania.

Analytical Neurochemistry Core

The Analytical Neurochemistry Core provide users with wherewithal to measure analytes (small molecules and proteins) of importance to normal neurochemical function and of salience to understanding the biochemical derangements that commonly occur in developmental disabilities.

Biostatistics and Bioinformatics Core

The Biostatistics and Bioinformatics Core supports IDDRC investigators in experimental design and biostatistical analysis of data from traditional sources, as well as studies that use genomic and functional genomic data.

Cellular Neuroscience Core

The Cellular Neuroscience Core provides our users with a state-of-the-art resource for the in vitro study of neurophysiology, neuropathology, and the preparation of neural model systems.

Neuroimaging Core

The rationale for the Neuroimaging Core is that the revolution in neuroimaging technology - a landmark achievement of contemporary neuroscience research – enables the in vivo scrutiny of the brain of people with developmental disabilities. The availability of this technology should facilitate studies that seek to understand mechanisms of developmental disabilities, to develop biomarkers, and to improve translation of therapies.